Pei He

9.1k total citations · 2 hit papers
30 papers, 3.0k citations indexed

About

Pei He is a scholar working on Oncology, Statistics and Probability and Pathology and Forensic Medicine. According to data from OpenAlex, Pei He has authored 30 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Statistics and Probability and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Pei He's work include Cancer Immunotherapy and Biomarkers (8 papers), Statistical Methods in Clinical Trials (6 papers) and CAR-T cell therapy research (4 papers). Pei He is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Statistical Methods in Clinical Trials (6 papers) and CAR-T cell therapy research (4 papers). Pei He collaborates with scholars based in United States, China and France. Pei He's co-authors include Achim Rittmeyer, Alan Sandler, Marcus Ballinger, Julien Mazières, Keunchil Park, Louis Fehrenbacher, Á. Artal, C. Lewanski, Daniel Waterkamp and Daniel S. Chen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Pei He

29 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

2016 2.1k citations Louis Fehrenbacher, Alexander I. Spira et al. The Lancet profile →
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

2016 477 citations Chongyang Zhang, Weigang Yuan et al. World Journal of Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pei He United States	12	2.1k	1.4k	625	390	388	30	3.0k
Mitsuhiro Takenoyama Japan	36	2.2k 1.0×	1.9k 1.4×	1.1k 1.7×	374 1.0×	306 0.8×	221	3.9k
Hiroaki Tanaka Japan	32	2.0k 0.9×	1.2k 0.9×	672 1.1×	522 1.3×	237 0.6×	172	3.5k
Shunchang Jiao China	30	1.9k 0.9×	977 0.7×	618 1.0×	655 1.7×	182 0.5×	144	3.4k
Shukui Qin China	25	1.9k 0.9×	1.5k 1.1×	256 0.4×	318 0.8×	211 0.5×	95	3.1k
Yoshito Akagi Japan	32	1.8k 0.9×	741 0.5×	363 0.6×	526 1.3×	187 0.5×	272	3.3k
Wenfeng Fang China	33	3.4k 1.6×	2.4k 1.7×	681 1.1×	890 2.3×	311 0.8×	201	4.9k
Biagio Ricciuti United States	33	2.6k 1.2×	1.7k 1.2×	481 0.8×	774 2.0×	322 0.8×	161	3.8k
Kyung Hwan Kim South Korea	26	994 0.5×	485 0.4×	509 0.8×	326 0.8×	153 0.4×	95	2.2k
Yukio Hosomi Japan	28	2.5k 1.2×	2.1k 1.5×	285 0.5×	429 1.1×	236 0.6×	189	3.7k
Hiroyuki Takamura Japan	26	993 0.5×	416 0.3×	293 0.5×	453 1.2×	362 0.9×	150	2.5k

Countries citing papers authored by Pei He

Since Specialization

Citations

This map shows the geographic impact of Pei He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pei He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pei He more than expected).

Fields of papers citing papers by Pei He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pei He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pei He. The network helps show where Pei He may publish in the future.

Co-authorship network of co-authors of Pei He

This figure shows the co-authorship network connecting the top 25 collaborators of Pei He. A scholar is included among the top collaborators of Pei He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pei He. Pei He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fang, Min, et al.. (2024). Acupressure bladder meridian alleviates anxiety disorder in rats by regulating MAPK and BDNF signal pathway. Physiology & Behavior. 283. 114534–114534. 4 indexed citations

Yang, Yiqun, et al.. (2024). Genetic effects and causal association analyses of 14 common conditions/diseases in multimorbidity patterns. PLoS ONE. 19(5). e0300740–e0300740. 2 indexed citations

Zhang, Qi, et al.. (2023). Acupressure bladder meridian alleviates anxiety disorder via HMGB1. International Immunopharmacology. 127. 111415–111415. 5 indexed citations

Yu, Xinghao, Bo Lin, Yiqun Yang, et al.. (2022). Systematic Evaluation of Rheumatoid Arthritis Risk by Integrating Lifestyle Factors and Genetic Risk Scores. Frontiers in Immunology. 13. 901223–901223. 7 indexed citations

Peng, Luke, Amol Narang, Noura Radwan, et al.. (2018). Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy. Urologic Oncology Seminars and Original Investigations. 36(6). 309.e7–309.e14. 9 indexed citations

He, Pei, et al.. (2017). The single nucleotide polymorphism of DMRT1 is associated with oligospermia. Biomedical Research-tokyo. 28(16). 7172–7176. 2 indexed citations

Cortinovis, Diego, Joachim von Pawel, K. Syrigos, et al.. (2017). Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK. Annals of Oncology. 28. v468–v468. 4 indexed citations

Rittmeyer, Achim, David C. Smith, Johan Vansteenkiste, et al.. (2017). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR). Pneumologie. 71(S 01). S1–S125. 4 indexed citations

Zhang, Chongyang, Weigang Yuan, Jianguo Fang, et al.. (2016). Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials. PLoS ONE. 11(8). e0161792–e0161792. 38 indexed citations

10.

Zhang, Chongyang, Weigang Yuan, Pei He, Jiahui Lei, & Chunxu Wang. (2016). Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World Journal of Gastroenterology. 22(48). 10512–10512. 477 indexed citations breakdown →

11.

Fehrenbacher, Louis, Alexander I. Spira, Marcus Ballinger, et al.. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 387(10030). 1837–1846. 2112 indexed citations breakdown →

12.

Narang, Amol, S.P. Robertson, Pei He, et al.. (2015). Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. International Journal of Radiation Oncology*Biology*Physics. 94(2). 254–262. 31 indexed citations

13.

He, Pei, et al.. (2015). Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies. British Medical Bulletin. 114(1). 17–27. 10 indexed citations

14.

He, Pei, Tze Leung Lai, & Zheng Su. (2015). Design of clinical trials with failure-time endpoints and interim analyses: An update after fifteen years. Contemporary Clinical Trials. 45(Pt A). 103–112. 5 indexed citations

15.

He, Pei & Zheng Su. (2015). A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects. SHILAP Revista de lepidopterología. 1. 28–31. 6 indexed citations

16.

He, Pei. (2014). Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints. Contemporary Clinical Trials. 38(2). 333–337. 6 indexed citations

17.

He, Pei, George Kong, & Zheng Su. (2013). Estimating the survival functions for right-censored and interval-censored data with piecewise constant hazard functions. Contemporary Clinical Trials. 35(2). 122–127. 11 indexed citations

18.

He, Pei, et al.. (2009). Relationship between IL-10 promoter gene polymorphisms and the susceptibility to endometriosis. Hereditas (Beijing). 31(5). 479–484. 4 indexed citations

19.

He, Pei, et al.. (2006). Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: Effects of aminoguanidine. Atherosclerosis. 190(1). 53–61. 22 indexed citations

20.

Xiong, Yan, et al.. (2006). Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein. Nitric Oxide. 16(1). 94–103. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact